Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amylyx Pharmaceuticals (AMLX) Non-cash Items: 2021-2024

Historic Non-cash Items for Amylyx Pharmaceuticals (AMLX) over the last 4 years, with Dec 2024 value amounting to $3.7 million.

  • Amylyx Pharmaceuticals' Non-cash Items rose 1940.61% to $52.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $52.6 million, marking a year-over-year increase of 1940.61%. This contributed to the annual value of $3.7 million for FY2024, which is 5.32% down from last year.
  • Amylyx Pharmaceuticals' Non-cash Items amounted to $3.7 million in FY2024, which was down 5.32% from $3.9 million recorded in FY2023.
  • In the past 5 years, Amylyx Pharmaceuticals' Non-cash Items ranged from a high of $15.6 million in FY2021 and a low of $2.1 million during FY2022.
  • Its 3-year average for Non-cash Items is $3.2 million, with a median of $3.7 million in 2024.
  • In the last 5 years, Amylyx Pharmaceuticals' Non-cash Items plummeted by 86.85% in 2022 and then skyrocketed by 88.65% in 2023.
  • Amylyx Pharmaceuticals' Non-cash Items (Yearly) stood at $15.6 million in 2021, then slumped by 86.85% to $2.1 million in 2022, then spiked by 88.65% to $3.9 million in 2023, then dropped by 5.32% to $3.7 million in 2024.